

Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

5th/ 3rd Floor,
YMCA Cultura Center Building,
1, Jai Singh Road, New Delhi – 110 001.
Date: 05.06.2026

To,
Dr. Rajeev Singh Raghuvanshi,
Drugs Controller General of India,
Central Drugs Standard Control Organization,
FDA Bhawan, Kotla Road, New Delhi – 110 002.

Subject: Information regarding imports and availability of APIs/KSMs for Carboplatin and Cisplatin formulations – reg.

Sir,

As you may be aware, concerns regarding the nationwide shortage of the critical anti-cancer drugs Carboplatin and Cisplatin have been raised through multiple channels. In this regard, a meeting was held on 04.06.2026 at NPPA with the manufacturer of these formulations and their APIs/KSMs regarding the reported shortage of Carboplatin and Cisplatin formulations in the country.


2. During the meeting, major manufacturers reported difficulties in obtaining platinum-based APIs and their key starting materials (KSMs). They stated that global supply disruptions have led to irregular availability of APIs, while shortages of critical KSMs such as Potassium Tetra Chloroplatinate (PTCP) and Potassium Di Chlorodiammineplatinatate (PDCP) have further affected production.

3. In order to assess the factors affecting the availability of these formulations and to facilitate appropriate policy intervention, it is requested that following information may kindly be provided at earliest:

- a) Quantity of Carboplatin, Cisplatin formulations and their APIs, KSMs imported during all quarters of 2025-26 and first quarter of 2026-27 till date
- b) Name and contact details of manufacturers registered for production, Import and Export of Carboplatin and Cisplatin formulations in India
- c) Whether any issue/challenges are there in importing the APIs/KSMs for these formulations

This issues with approval of the Competent Authority.

Yours faithfully,


05/06/2026
(Bhiva Ram Yadav)
Assistant Director